KPRXNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as KPHMW
KIORA PHARMACEUTICALS INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026
$2.38−0.02 (-0.83%)
Close on Oct 19, 2026
- Market cap
- $14.70M
- P/E (TTM)
- –
- Dividend yield
- –
Kiora Pharmaceuticals statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Kiora Pharmaceuticals | Industry median |
|---|---|---|
| Market Cap | $10.53M | $166.30M |
| Enterprise Value | -$6.31M | $88.19M |
| PB Ratio | 0.62 | 2.03 |
| P/TBV Ratio | 0.71 | 2.29 |
Income (trailing twelve months)
| Measure | Kiora Pharmaceuticals | Industry median |
|---|---|---|
| Operating Income | -$12.83M | -$21.40M |
| Pretax Income | -$12.28M | -$14.34M |
| Net Income | -$10.99M | -$22.46M |
| EBITDA | -$12.79M | -$16.91M |
| EPS (Diluted) | -$2.57 | -$0.83 |
Returns
| Measure | Kiora Pharmaceuticals | Industry median |
|---|---|---|
| Return on Equity (ROE) | -56.4% | -53.2% |
| Return on Assets (ROA) | -39.4% | -40.9% |
| Return on Invested Capital (ROIC) | -1374.1% | -32.4% |
| Return on Capital Employed (ROCE) | -59.9% | -38.1% |
Balance sheet
| Measure | Kiora Pharmaceuticals | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $16.84M | $61.43M |
| Net Cash (Debt) | $16.84M | $15.35M |
| Net Cash Per Share | $3.81 | $0.66 |
| Equity (Book Value) | $16.86M | $49.09M |
| Book Value Per Share | $3.81 | $1.37 |
| Tangible Book Value | $14.79M | $23.52M |
| Working Capital | $18.89M | $76.81M |
Financial position
| Measure | Kiora Pharmaceuticals | Industry median |
|---|---|---|
| Current Ratio | 8.97 | 3.34 |
| Quick Ratio | 7.56 | 2.44 |
Cash flow (trailing twelve months)
| Measure | Kiora Pharmaceuticals | Industry median |
|---|---|---|
| Operating Cash Flow | -$8.51M | -$12.35M |
| Capital Expenditures | -$107.07K | -$1.08M |
| Free Cash Flow | -$8.61M | -$20.22M |
| FCF Per Share | -$1.95 | -$0.42 |
Efficiency
| Measure | Kiora Pharmaceuticals | Industry median |
|---|---|---|
| Profits Per Employee | -$3.14K | -$703.34K |
| Employee Count | 3,500 | 74 |
Dividends and yields
| Measure | Kiora Pharmaceuticals | Industry median |
|---|---|---|
| Earnings Yield | -104.3% | -23.3% |
| FCF Yield | -81.8% | -8.72% |
Shares
| Measure | Kiora Pharmaceuticals | Industry median |
|---|---|---|
| Shares Outstanding | 4,424,390 | 58,127,000 |
| Shares Change (YoY) | 12.0% | 10.9% |
| Shares Change (QoQ) | 10.9% | 0.54% |
| Float | 4,291,990 | 49,136,700 |
| Shares Held by Insiders | 2.99% | 11.6% |
| Shares Held by Institutions | 25.0% | 59.4% |
Taxes
| Measure | Kiora Pharmaceuticals | Industry median |
|---|---|---|
| Income Tax | -$1.29M | $79.87K |
Scores
| Measure | Kiora Pharmaceuticals | Industry median |
|---|---|---|
| Altman Z-Score | -9.26 | -0.22 |
| Piotroski F-Score | 3 | 4 |
Calculated by StockData from Kiora Pharmaceuticals's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.